TrialsgrambetaRCTs are beautiful

MODIFY I/II

2017

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

In 2,655 patients receiving antibiotics for Clostridium difficile infection, a single dose of bezlotoxumab reduced recurrent CDI at 12 weeks compared with placebo.

Result

Primary endpoint: Recurrent CDI at 12 weeks

Recurrence 17 % vs 28 % (MODIFY I) and 16 % vs 26 % (MODIFY II); ARR ~10 pp; NNT ≈ 10.

Original publication
Subtopic
Recurrence prevention
Design
Two double-blind RCTs (pooled)
Relevance
Supporting: context rather than must-know.
Source
Wilcox MH, et al. N Engl J Med. 2017;376(4):305-317.doi 10.1056/NEJMoa1602615

Discussion & critique

Bezlotoxumab as adjunctive recurrence prevention: most useful in patients ≥65 years, immunocompromised or with severe or repeated CDI.

Discussed in podcasts